Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
AMBRILIA VALIDATES ITS TARGETED DELIVERY TECHNOLOGY FOR CANCER IN VIVO
July 12th, 2008
Ambrilia Biopharma Inc. (TSX:AMB) reported that it demonstrated and validated the in vivo proof-of-concept with its NGR-delivery technology applied to a carrier containing a siRNA (small interfering RNA). Data in animal tumor models showed efficient siRNA delivery to the tumor tissue, internalization and suppression of a cancer-promoting gene (oncogene). Such genes are essential to the growth of a number of tumors. In the past years, a number of oncogenes have been suppressed with RNA interference (RNAi), which can be achieved by siRNAs, showing the potential for therapeutic applications in humans. "This validation represents another significant step forward in our...
Source: Law & Health Weekly (2008-07-12)
|
